Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Nitric Oxide ; 4(5): 496-504, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11020338

ABSTRACT

The Mutatect system is a mouse tumor line in which mutations at the hypoxanthine phosphoribosyltransferase (Hprt) locus can be readily detected both in vitro and in vivo. We have previously shown that the nitric oxide-generating drugs, glyceryl trinitrate (GTN) and sodium nitroprusside (SNP), can induce mutations that are readily detected in these cells. In the present report, we have tested the effect of glutathione depletion by buthionine sulfoximine (BSO) on cytotoxicity and mutagenicity by these two drugs. Exposure for 24 h to either drug (123 microM GTN; 500 microM SNP) induced mutations with relatively little cytotoxicity. Pretreatment with 50 microM BSO for 24 h, and then removal at the time of GTN or SNP addition, enhanced cytotoxicity to a modest extent. However, mutagenicity induced by both GTN and SNP was largely abolished. BSO did not affect nitrite accumulation in the medium over a 24-h period, indicating no inhibition of bioactivation of GTN or SNP. Maintaining BSO in the medium for 24 h prior and throughout the period of exposure to GTN or SNP produced a similar effect on mutations. N-Acetylcysteine and oxothiazolidine-4-carboxylate, drugs that are used to increase intracellular glutathione, also blocked mutations. We postulate that a product of the reaction between nitric oxide and intracellular glutathione, such as GSNO or some species derived from it, is promutagenic.


Subject(s)
Glutathione/metabolism , Mutagenesis/drug effects , Mutagens/toxicity , Nitric Oxide Donors/toxicity , Acetylcysteine/pharmacology , Animals , Buthionine Sulfoximine/pharmacology , Cell Survival/drug effects , Gamma Rays , Hypoxanthine Phosphoribosyltransferase/genetics , Mice , Mutagenesis/genetics , Mutagenesis/radiation effects , Nitric Oxide/metabolism , Nitric Oxide Donors/antagonists & inhibitors , Nitrites/metabolism , Nitroglycerin/antagonists & inhibitors , Nitroglycerin/toxicity , Nitroprusside/toxicity , Pyrrolidonecarboxylic Acid , Thiazoles/pharmacology , Thiazolidines , Tumor Cells, Cultured
2.
Am J Pathol ; 156(2): 509-18, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10666380

ABSTRACT

Mutatect MN-11 is a tumor line that can be grown subcutaneously in syngeneic C57BL/6 mice. The frequency of spontaneously arising mutants at the hypoxanthine phosphoribosyltransferase (Hprt) locus was observed to be elevated as a result of in vivo growth. The objective of the present study was to identify factors in the tumor microenvironment that might explain this increase in mutant frequency (MF). When tumors were examined histologically, neutrophils were found to be the predominant infiltrating cell type. Quantitative estimates of the number of neutrophils and MF of tumors in different animals revealed a statistically significant correlation (r = 0.63, P < 0.0001). Immunohistochemical analysis for inducible nitric oxide synthase (iNOS) demonstrated its presence, mainly in neutrophils. Biochemical analysis of tumor homogenates for nitric oxide synthase (NOS) activity indicated a statistically significant correlation with MF (r = 0.77, P < 0.0001). Nitrotyrosine was detected throughout the tumor immunohistochemically; both cytoplasmic and nuclear staining was seen. To increase the number of infiltrating neutrophils, tumors were injected with chemoattractant interleukin-8 and prostaglandin E2. This produced a statistically significant increase in neutrophil content (P = 0.005) and MF (P = 0.0002). As in control MN-11 tumors, neutrophil content and MF were strongly correlated (r = 0.63, P = 0. 003). Because neutrophils are a potential source of genotoxic reactive oxygen and/or nitrogen species, our results support the notion that these tumor-infiltrating cells may be mutagenic and contribute to the burden of genetic abnormalities associated with tumor progression.


Subject(s)
Fibrosarcoma/enzymology , Fibrosarcoma/pathology , Mutation , Neutrophils/physiology , Nitric Oxide Synthase/metabolism , Animals , Cell Movement/drug effects , Dinoprostone/pharmacology , Drug Combinations , Female , Fibrosarcoma/genetics , Gene Frequency/drug effects , Genetic Variation , Immunohistochemistry , Injections , Injections, Subcutaneous , Interleukin-8/pharmacology , Mice , Mice, Inbred C57BL , Mutation/genetics , Neoplasm Transplantation/methods , Neutrophils/drug effects , Nitric Oxide Synthase Type II , Tumor Cells, Cultured , Tyrosine/analogs & derivatives , Tyrosine/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...